Literature DB >> 27222255

Downregulation of lncRNA CASC2 by microRNA-21 increases the proliferation and migration of renal cell carcinoma cells.

Yunjie Cao1, Renfang Xu1, Xianlin Xu1, Yaojun Zhou1, Li Cui1, Xiaozhou He1.   

Abstract

Several long non-coding RNAs (lncRNAs) have been identified that may have a crucial role in tumor progression and metastasis. The lncRNA cancer susceptibility candidate 2 (CASC2) has previously been reported to act as a tumor suppressor gene in glioma and colorectal cancer. However, the expression and function of CASC2 in renal cell carcinoma (RCC) remains to be elucidated. The present study confirmed that CASC2 was downregulated in human RCC tissues and human RCC cell lines (786‑O and A498). Restoration of CASC2 expression via transfection with a pcDNA3.1(+)‑CASC2 vector was able to inhibit cell proliferation and migration in 786‑O and A498 cells, as compared with in the cells transfected with a pcDNA3.1(+) empty vector. MicroRNA‑21 (miR‑21) has been reported to be upregulated in human RCC tissues and cell lines, and is associated with the malignant progression of RCC. In the present study, bioinformatics analysis and dual‑luciferase reporter assays confirmed that CASC2 was a direct target gene of miR‑21. miR‑21 was able to decrease the expression of CASC2 in 786‑O and A498 cells. Furthermore, overexpression of miR‑21 partly abrogated CASC2‑mediated inhibition of 786‑O and A498 cell proliferation and migration. The present study provides evidence indicating that CASC2 targeted by miR‑21 acts as a tumor suppressor in RCC. Therefore, CASC2 may be considered a novel target for the diagnosis and treatment of RCC.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27222255     DOI: 10.3892/mmr.2016.5337

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  31 in total

Review 1.  CASC2: An emerging tumour-suppressing long noncoding RNA in human cancers and melanoma.

Authors:  Xin Yu; Heyi Zheng; Gary Tse; Lin Zhang; William Ka Kei Wu
Journal:  Cell Prolif       Date:  2018-08-09       Impact factor: 6.831

Review 2.  Long non-coding RNAs: a valuable biomarker for metabolic syndrome.

Authors:  Mohammad Rashidmayvan; Reza Sahebi; Majid Ghayour-Mobarhan
Journal:  Mol Genet Genomics       Date:  2022-07-19       Impact factor: 2.980

Review 3.  Epithelial-to-mesenchymal transition in thyroid cancer: a comprehensive review.

Authors:  Heewa Shakib; Sadegh Rajabi; Mohammad Hossien Dehghan; Farideh Jalali Mashayekhi; Nahid Safari-Alighiarloo; Mehdi Hedayati
Journal:  Endocrine       Date:  2019-08-04       Impact factor: 3.633

Review 4.  Molecular Crosstalking among Noncoding RNAs: A New Network Layer of Genome Regulation in Cancer.

Authors:  Marco Ragusa; Cristina Barbagallo; Duilia Brex; Angela Caponnetto; Matilde Cirnigliaro; Rosalia Battaglia; Davide Barbagallo; Cinzia Di Pietro; Michele Purrello
Journal:  Int J Genomics       Date:  2017-09-24       Impact factor: 2.326

5.  Long Non-Coding RNA Cancer Susceptibility Candidate 2a (CASC2a) Is a Marker of Early Recurrence After Radical Cystectomy in Patients with Urothelial Carcinoma of the Bladder.

Authors:  Zhen Li; Kang-Er Wang; Xie-Lai Zhou; Jin Zhou; Chun-Hua Ye
Journal:  Med Sci Monit       Date:  2018-01-23

6.  LincRNA FEZF1-AS1 contributes to the proliferation of LAD cells by silencing p57 expression.

Authors:  Shuai Jin; Siyu Chen; Yongfu Ma; Bo Yang; Yang Liu
Journal:  Oncotarget       Date:  2017-09-23

Review 7.  Long non-coding RNAs in renal cell carcinoma: A systematic review and clinical implications.

Authors:  Ming Li; Ying Wang; Liang Cheng; Wanting Niu; Guoan Zhao; Jithin K Raju; Jun Huo; Bin Wu; Bo Yin; Yongsheng Song; Renge Bu
Journal:  Oncotarget       Date:  2017-07-18

8.  Functional prediction of long non-coding RNAs in ovarian cancer-associated fibroblasts indicate a potential role in metastasis.

Authors:  Fatemeh Vafaee; Emily K Colvin; Samuel C Mok; Viive M Howell; Goli Samimi
Journal:  Sci Rep       Date:  2017-09-04       Impact factor: 4.379

9.  Long non-coding RNA BRE-AS1 inhibits the proliferation, migration, and invasion of cancer cells in triple-negative breast cancer and predicts patients' survival by downregulating miR-21.

Authors:  Jianchao Gao; Sisi Wang; Zhisheng Zhang; Jun Li
Journal:  BMC Cancer       Date:  2021-06-28       Impact factor: 4.430

10.  LncRNA RP11-436H11.5, functioning as a competitive endogenous RNA, upregulates BCL-W expression by sponging miR-335-5p and promotes proliferation and invasion in renal cell carcinoma.

Authors:  Kefeng Wang; Wei Jin; Yan Song; Xiang Fei
Journal:  Mol Cancer       Date:  2017-10-25       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.